EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE:GSK) a annoncé lundi que l'Agence européenne des médicaments (EMA) a accepté d'examiner sa demande d'autorisation de mise sur le marché pour le linerixibat, un traitement expérimenta ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

– GSK a annoncé lundi que l’Agence européenne des médicaments a accepté d’examiner la demande d’autorisation de mise sur le ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

GSK annonce que l'Agence européenne des médicaments a accepté d'examiner la demande d'autorisation de mise sur le marché du ...

THIS YEAR, the vibrant city of Amsterdam, the Netherlands played host to the European Association for the Study of ...

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

Linerixibat also significantly reduced itch-related sleep interference, with an LS mean difference of -0.53 (p=0.024). Fifty-six percent of patients treated with linerixibat achieved a clinically ...